Psoriasis is a chronic, immune-mediated skin disorder that affects 1-3% of the general population worldwide. While … considered a non-life-threatening disease, psoriasis represents a social and financial burden for patients and the healthcare …, patients with a diagnosis of psoriasis usually need lifelong care, which also means a lifetime of expenses. We aimed to conduct …

clinical variables, our model included health service utilisation variables related to psoriasis, and explained higher …

Objective: Recently a number of new therapies have been introduced to treat psoriasis, but concerns have been expressed … about their high cost. The purpose of this study was to determine whether most psoriasis treatments lie within the accepted … range of cost-utility. Methodology: 32 patients with moderate to severe psoriasis were administered the Euro-Qol 5 Dimension …

a comparison of adalimumab and etanercept for the treatment of psoriasis. IPD from trials of adalimumab versus placebo … trials. Symptom improvements of ≥75% and ≥90% (as measured by the Psoriasis Area and Severity Index [PASI] score at … psoriasis. …

cyclosporin in patients with chronic plaque psoriasis. Methods: A cost-effectiveness analysis was performed in parallel with a … plaque psoriasis inadequately controlled with topical treatment. Study perspective: The study was conducted from a societal … cyclosporin in patients with chronic plaque psoriasis. …